Indiana University Foundation, Inc.

In 1974, Dr. Lawrence Einhorn developed a new drug therapy for testicular cancer, raising survival rates from 5% to over 95%, saving hundreds of thousands of lives and establishing a foundation of research excellence at Indiana University.

Study uses three cohorts (discovery, validation, testing) to discover, prioritize, validate, and test biomarkers for suicidality, integrating microarray and RNA sequencing data. Key steps include discovery of biomarkers tracking suicidality, prioritization through Convergent Functional Genomics, validation in postmortem suicide completers, and testing in independent psychiatric cohorts for predicting suicidality severity and future hospitalizations. Top candidate biomarkers are identified and tested for clinical utility, with a focus on gender-specific predictions and personalized medicine.